Transactions

Following discussions between the health Minister Dr Aaron Motsoaledi and Aspen Pharmacare Senior Executive Mr Stavros Nicolaou in Johannesburg, Aspen Pharmacare released 30 000 packs of Tenofovir (TDF) for the Limpopo depot earlier today. Further releases to this province are expected during the course of next week. Aspen Pharmacare is one of the two (2) companies supplying ARVs to government hospitals. Reports have recently suggested that there were shortages that were being encountered in the availability of ARVs. In a media conference in Johannesburg yesterday, the health Minister dispelled these reports of complete unavailability of these drugs, indicating instead that there was a decline in stock-levels which did not necessarily translate in patients not getting their ARVs. Health Minister has expressed his happiness at news that stock-levels in the Limpopo depot have been increased. “It’s an important development and it actually demonstrates our commitment to ensuring that at no point are our patients compromised. We are continuously monitoring the situation on a daily basis and I must commend Aspen for their quick response in dealing with the situation”, said the health Minister. For media enquiries please contact: Fidel Hadebe – Department of Health: 079 517-3333 or Stavros Nicolaou – Senior Executive: Aspen Pharmacare: 082 458-3135. Issued by the Department of Health

Statement by Aspen on the reported Tenofovir (TDF) public sector supply shortages Johannesburg: Since March this year there have been sporadic reports of Tenofovir (TDF) supply shortages in certain provinces and hospitals where patients are receiving ARV treatment. These reports seem to have manifested again this week and some allegations have emerged that the contracted TDF suppliers are in part responsible for these shortages. Aspen, as the Southern Hemisphere’s largest Pharmaceutical Manufacturer and the leading supplier of ARV’s to both the SA private and public sector can in no way condone these shortages, even if it is to a small group of patients and accordingly the company wishes to publicly clarify the following: • At a press briefing earlier today Minister of Health, Dr Aaron Motsoaledi confirmed that the National Department of Health (NDOH) had checked all 10 depots nationally and all 10 have TDF. • Aspen has the state contract to supply 70% of the required state volume for TDF for a two year period, commencing on 1 January 2011 and ending on 31 December 2012. It is required to deliver within 6 weeks of confirmation of received orders. • Initial offtakes for TDF during the first year of the tender contract were extremely low, with monthly orders placed on Aspen averaging around 250 000 monthly treatment packs. This was largely because donor fund procured TDF product displaced much of the tender volumes. • This donor fund procured inventory ran out by December 2011 and it became necessary for the current suppliers to respond, by immediately scaling up production. • The transition from donor stock to state procured TDF was not a smooth transition, with some provinces and institutions underforecasting demand and/or placing orders either erratically or only once stock levels had dwindled significantly. Consequently, some institutions remained well stocked, whilst others ran into problems. • Despite this, For example, NDOH’s forecast for 70% of the volume over the past 3 months from March to May 2012 required Aspen to supply 668 000 packs per month or 2 million packs for this period. Over this 3 month period, Aspen has supplied 2,4 million packs, exceeding its contractual requirement by more than 400 000 packs. This averages out to approximately 860 000 packs per month. Aspen has been advised by the NDOH that it is needed to over-supply on its contractual commitment because the supplier required to supply the other 30% of the TDF tender is unable to do so. Aspen has accordingly stepped in and is manufacturing in excess of its contractual requirements. By way of example, Aspen has supplied 1,140 million treatment packs for the month of May to the NDOH, exceeding by 350 000 packs its monthly contractual requirement. • As this crisis began to unfold, Aspen acting in consultation with the NDOH, has been able to step up both its raw material imports and allocation of manufacturing capacity to meet this increased demand. It has been able to do so with requisite flexibility and in a short space of time. • Given the current situation, Aspen will continue to commit the required capacity from now until the end of the tender period, to ensure that it not only meets its own tender volume obligations, but it is able to step in and supply the quantities that other suppliers are unable to. • Aspen views supply security and the maintenance of the integrity of the South African Public ARV programme as a National imperative. It also views its commitment to supply timeously and according to its committed quantities with equal importance. To this end, Aspen has an excellent track record in the manufacture, supply and delivery of ARV’s to the SA Government. This is not the first time Aspen has had to step in to supply where importers who had won the contract for other ARVs have been unable to supply in the current contract period. This has been the case, for example, where Aspen has had to take over supply for Stavudine 30mg and Lamivudine 150mg in the current two year contract period. Aspen has thus continued to supply on its own commitments, in addition to that where other suppliers have been unable to supply. In conclusion, Aspen is able to confirm that it is presently meeting both its contractual terms and supply volumes for TDF that it is required to in terms of the current ARV tender. The Company can also confirm that it presently has no backorder for TDF, meaning that all remaining orders in the system are within the 6 week delivery period. The company will supply around 1,1 million packs in June 2012, which will again exceed monthly NDOH forecast by 400 000 units.

Aspen Pharmacare Holdings Limited (“Aspen”) (Incorporated in the Republic of South Africa) Registration Number 1985/002935/06 Share code APN – ISIN: ZAE000066692 (“Aspen Holdings”) ASPEN ANNOUNCES MULTI-TERRITORY ACQUISITION OF GSK OTC PRODUCTS FOR R2.1 BILLION Durban, South Africa: Aspen Holdings is pleased to announce that the Aspen Group (“Aspen”) has reached agreement with GlaxoSmithKline plc (“GSK”) for the acquisition of a portfolio of established over-the-counter (“OTC”) products (“the products”) in selected territories including South Africa, Australia and Brazil. The deal is valued at GBP 164 million (ZAR 2.1 billion at ZAR 12.6/GBP). Stephen Saad, Aspen Group Chief Executive said, “The products acquired through these transactions are an excellent geographic fit with Aspen’s existing footprint and will allow for significant strengthening of Aspen’s OTC offering in all of the territories concerned. The products have considerable established brand equity, which Aspen intends to leverage through increased promotion and plans to expand through line extensions. The transactions will also provide impetus in territories where Aspen is seeking to grow critical mass such as Latin America and South East Asia.” The deal comprises two transactions (“the transactions”): The acquisition by Aspen Holdings of the products sold in the territories of South Africa, Namibia, Botswana, Swaziland, Lesotho, Zambia and Zimbabwe for GBP 20 million (ZAR 252 million at ZAR 12.6/GBP) (“the Southern Africa transaction”); and The acquisition by Aspen Global Incorporated, a wholly owned subsidiary of Aspen Holdings incorporated in Mauritius, of the products sold in the rest of the world, but excluding the territories of North America and Europe (which are the subject of separate transactions concluded between GSK and third parties), for GBP 144 million (ZAR 1.8 billion at ZAR 12.6/GBP (“the Rest of the World transaction”). The Southern Africa transaction is subject to, amongst others, the following conditions precedent: The approval of the South African competition authorities; and The approval of the Financial Surveillance Department of the South African Reserve Bank. In addition, the Southern Africa transaction in respect of Namibia and Swaziland only, is subject to and conditional upon the approval of the respective competition authorities in those countries. The effective date of the Southern Africa transaction will be the last business day of the calendar month in which the last of the applicable conditions precedent is fulfilled. The Rest of the World transaction is unconditional and is effective from 1 May 2012 save in respect of: the product, Zantac, which is marketed, distributed and sold in Australia and New Zealand which is subject to the approval of the Australian competition authorities; the portion of the Rest of the World transaction relating to Kenya which is subject to the approval of the Kenyan competition authorities; and the portion of the Rest of the World transaction relating to Tanzania which is subject to the approval of the Tanzanian competition authorities. (collectively, “the Rest of the World conditions”). The transaction value of the products which are subject to the Rest of the World conditions is GBP 23.1 million (ZAR 291 million at ZAR 12.6/GBP). The elements of the Rest of World transaction which are subject to the Rest of the World conditions will be effective on the last business day of the month in which the respective Rest of the World conditions are fulfilled. In terms of the transactions the marketing and distribution of the products will transition from GSK to Aspen over periods of time varying by country. Existing manufacturing arrangements for the products will be assumed by Aspen. Funding The transactions will be funded from existing cash resources, existing credit facilities and new debt, the latter funding approximately 50% of the transaction. Arrangements for the raising of the new debt have been finalised. The Products: The products comprise well established OTC brands of proven performance. The main areas of therapeutic treatment of the products are analgesic, gastro-intestinal and respiratory. Other areas covered include dermatology, infant care, vitamins and minerals. The leading products are recognised household brands such as Phillips Milk of Magnesia, Dequadin, Solpadeine, Cartia, Zantac and Borstol. GSK reports that the products which are the subject of the transactions recorded revenue of GBP 59.3 million in calendar 2011. In accordance with Aspen’s segmental reporting this revenue is split as follows: Asia Pacific: GBP 21.4 million; South Africa: GBP 7.3 million; Sub-Saharan Africa: GBP 5.0 million; and International: GBP 25.6 million (of which GBP 17.0 million is in Latin America). Aspen expects the transactions to be earnings accretive from the outset. GSK’s announcement of the transaction can be accessed from their website by clicking on http://www.gsk.com/media/index.htm. Issued by: Shauneen Beukes, Shauneen Beukes Communications Tel: +27 (012) 661-8467 : Cell: +27 82 389 8900 On Behalf Of: Stephen Saad, Aspen Group Chief Executive Tel: +27 (031) 580-8603 Gus Attridge, Aspen Deputy Group Chief Executive Tel: +27 (031) 580-8605 Roshni Gajjar, Aspen Investor Relations Tel: +27 (041) 407-2952 : Cell: +27 82 879 1826

Johannesburg. Aspen (APN), South Africa’s leading pharmaceutical company, has announced that Irish-based Tibotec Pharmaceuticals has granted it a non-exclusive license to manufacture, market and distribute the Anti-retroviral (“ARV”) compound, rilpivirine hydrochloride (TMC278), pending approval of the molecule which could then be prescribed for patients commencing ARV treatment for the first time as well as for those who have previous ARV treatment experience. “This agreement further strengthens Aspen’s close working relationship with Tibotec in the supply of ARV’s and will further expand Aspen’s already extensive portfolio of HIV/AIDS medicines, thereby providing patients and physicians with increased clinical options”, said Stavros Nicolaou, Aspen Senior Executive. “TMC 278 is being viewed as a compound with a number of potential benefits over existing treatments and is set to play an important role in the future management of HIV and AIDS. It is well tolerated, has a long half-life and allows once-daily dosing.” The agreement entitles Aspen to manufacture TMC278 25 mg and to market TMC278 throughout sub-Saharan Africa (“SSA”), including South Africa. Fixed-dose combinations are, in certain instances, preferred by public health treatment programs and contain multiple molecules formulated into a single tablet to ease dosage management for patients. Tibotec has chosen to collaborate with select manufacturers in order to increase access to a sustainable supply of TMC278 in areas of high HIV/AIDS prevalence.

Johannesburg. Aspen (APN), South Africa’s leading pharmaceutical company, has announced that all conditions precedent have been met for it to acquire the pharmaceutical business of Australian-based Sigma Pharmaceuticals Limited (“Sigma”). The acquisition was approved following the extraordinary meeting of Sigma shareholders held on 14 January 2011. The effective date of change of ownership is 31 January 2011 and will position Aspen as the leading pharmaceutical company in Australia by volume of scripts generated. Stephen Saad, Aspen’s Group Chief Executive, said “Aspen is excited about this acquisition which enables the Group to accelerate growth in its Australian business and also to stimulate expansion plans into the broader Asia Pacific region. Aspen has already demonstrated its ability to supply high quality products at competitive prices across more than 100 worldwide territories. We have confidence in our Australian management team to leverage Aspen’s world-class procurement, manufacturing and distribution capabilities to ensure the expanded Aspen business delivers growing value in Australia.” In 2010 Aspen announced that it had reached a formal agreement to acquire Sigma’s pharmaceutical business on a debt-free basis for a cash consideration of AUD 900 million. The purchase consideration is approximately ZAR 6 148 million, based on an AUD/ZAR exchange rate of 0.1464 as at 13 January 2011. The transaction was however subject to a number of conditions precedent which have now been fulfilled. The Sigma business: Sigma, which has a 98-year legacy in Australia, is listed on the Australian Securities Exchange. Sigma’s pharmaceutical business, which is now being acquired by Aspen, consists of an extensive product portfolio of branded, generic and OTC products which include many well-known and trusted Australian brands as well as five manufacturing facilities. Sigma retains its wholesale business, and is one of three major wholesaler distributors in Australia. Aspen has concluded a long-term distribution agreement with Sigma. Rationale for the acquisition of Sigma’s pharmaceutical business: Aspen Australia, established in May 2001, markets and distributes pharmaceutical and consumer products. Aspen Australia has succeeded in delivering double-digit growth since inception as a greenfields operation in 2001, and recorded revenue of approximately AUD 180 million in the year ended 30 June 2010. Aspen Australia`s success has been achieved by sound management supported by an outstanding team which has consistently built Aspen`s branded product offering and reputation in Australia. Aspen Australia is currently ranked 7th in terms of volume of Australian scripts generated and its sales representative team has been voted number one in Australia. On the basis of this successful platform, the Sigma acquisition creates the following opportunities for Aspen: The extension of Aspen’s existing branded products business in Australia with the addition of Sigma’s branded, generics and OTC portfolios; An established point of entry into the Australian generics and OTC sectors for the introduction of Aspen`s pipeline of generic and OTC products; Securing a distribution channel for generic products through Sigma’s retained wholesale division; Providing additional opportunities to launch Aspen’s prolific product pipeline; Leveraging Aspen’s global manufacturing experience, expertise and capability through an Australian-based manufacturing presence; and Creating a foundation for further development of Aspen`s business in the Asia Pacific region. Based upon the historic performance of Aspen and Sigma in the Australian market, the combination of Sigma’s pharmaceutical business with Aspen’s existing business in Australia should lead to 1 in every 8 Australian prescriptions being written for an Aspen product and result in Aspen being ranked first by volume of scripts generated in Australia. Issued By: Shauneen Beukes, Shauneen Beukes Communication Tel: +27 12 661 8467; Cell: +27 82 389 8900 On Behalf of: Stephen Saad, Aspen Group Chief Executive Tel: +27 31 580 8601 Gus Attridge, Aspen Deputy Group Chief Executive Tel: +27 31 580 8602 Roshni Gajjar, Aspen Investor Relations Tel: +27 31 580 8649; Cell: +27 82 789 1826

Aspen ARV tender bid is successfulFollowing the announcement of the Anti-Retroviral (ARV) Tender results by the South African National Treasury Department, Aspen Pharmacare Holdings Limited is pleased to announce that its South African operating company (Aspen) has been successful in winning a number of key products in the tender, including Efavirenz and Tenofovir, in spite of strong competition. The tender is effective for a period of two years, commencing 01 January 2011. Aspen secured more than 40% of the awarded tender value based upon expected future demand as published in the invitation to tender. The tender value is estimated to be R3.6 billion over 2 years. The South African ARV Tender is the largest of its kind in the world. Aspen has been a leading supplier to this tender since inception of the programme, providing a consistent and reliable supply of high-quality ARV products to the State. Aspen was awarded a share of the following products: Product/ % Awarded to Aspen Abacavir Solution 20mg/ml 40% Efavirenz Tablets 600mg 70% Lamivudine Scored Tablets 150mg 70% Nevirapine Tablets 200mg 40% Tenofovir Tablets 300g 70% Zidovudine Tablets 300mg 40% These tender results are further testament to Aspen’s cost competitiveness against both local and foreign suppliers. Aspen’s range of ARV’s are produced at its world-class manufacturing facilities in Port Elizabeth, South Africa. The Group has invested more than R2 billion over the last five years in extending its manufacturing capability and enhancing the existing facilities. This has resulted in unlocking capacity to accommodate growing demand from Aspen’s domestic and foreign territories and also contributed towards further optimising manufacturing efficiencies. In his response to the ARV Tender results, Aspen Group Chief Executive, Stephen Saad said: “These tender results confirm Aspen’s cost competitiveness and its credibility as a reliable supplier of pharmaceutical products. Aspen is proud to be able to contribute towards increasing access to affordable, high quality medicines in South Africa and thereby assist in the treatment of the HIV/AIDS pandemic.” Aspen’s portfolio of ARV’s supports close to 900 000 patients in South Africa daily. 14 December 2010 Sponsor: Investec Bank Limited Date: 14/12/2010 11:48:15 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.

By : Shauneen Beukes ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) (Registration number 1985/002935/06) Share code: APN ISIN: ZAE000066692 (“Aspen”) ANNOUNCEMENT REGARDING THE ACQUISITION OF THE PHARMACEUTICAL BUSINESS OF SIGMA PHARMACEUTICALS LIMITED (“SIGMA”) BY ASPEN 1. INTRODUCTION Aspen shareholders are referred to the detailed cautionary announcement released on the Securities Exchange News Service of the JSE Limited (“SENS”) on 21 May 2010, and to the related renewal and further cautionary announcements dated 7 July 2010 and 12 July 2010, respectively (“Cautionary Announcements”). Subsequent to the completion by Aspen of the due diligence process referred to in the Cautionary Announcements, Aspen Global Incorporated (“Aspen Global”), a 100% owned subsidiary of Aspen, submitted, to the Board of Directors of Sigma (“Sigma Board”), an offer (“Subsequent Offer”) to acquire the pharmaceutical business conducted by Sigma (“Pharmaceutical Business”) on a debt-free basis for a cash consideration of A$900 million (approximately ZAR5 871 million ). The Subsequent Offer, which the Sigma Board has undertaken to support, is subject to limited conditions precedent as detailed in paragraph 4.4 below. 2. DESCRIPTION OF SIGMA AND THE BUSINESS Sigma is a leading Australian Securities Exchange (“ASX”) listed Australian manufacturer and marketer of prescription, over-the-counter (“OTC”) and generic pharmaceutical products as well as a wholesale distributor of pharmaceutical and consumer products. The Pharmaceutical Business consists of the manufacture and marketing of pharmaceutical products. It has an extensive product portfolio comprising many well-known and trusted Australian brands which recorded sales revenue of A$671 million in the year to 31 January 2010. The generics range has approximately a 25% share of the growing Australian generics sector. The Pharmaceutical Business is also Australia’s largest pharmaceutical manufacturer. For further details on the Pharmaceutical Business, Aspen shareholders are referred to www.sigmaco.com.au. 3. RATIONALE FOR THE SUBSEQUENT OFFER Aspen has an existing operation in Australia (“Aspen Australia”), marketing and distributing pharmaceutical and consumer products. Established in 2001, Aspen Australia has an excellent record of growth with revenue of approximately A$180million recorded in the year to 30 June 2010. Aspen Australia’s success has been achieved by sound management supported by an outstanding team which has consistently built Aspen’s product offering and reputation in Australia. The implementation of the Subsequent Offer creates the following opportunities: Synergies arising out of the consolidation of Aspen Australia and the Pharmaceutical Business; An established point of entry to the Australian generics and OTC sectors for the introduction of Aspen’s pipeline of generic and OTC products; Strengthening Aspen’s position in the Australian market which will form the foundation for further development of Aspen’s business in the Asia Pacific region; and Incorporation of Australian manufacturing presence into Aspen’s global manufacturing capabilities. Aspen Global’s initial approach to Sigma referred to in the Cautionary Announcements was for the acquisition of the entire business of Sigma, including the wholesale business. The Subsequent Offer means that Sigma will continue as an ASX listed company focused on the wholesaling business. The construction of the Subsequent Offer was framed after lengthy engagement with Sigma and recognizes that Sigma possesses the critical skills to optimize the performance of the wholesaling business, an activity in which Aspen does not have past experience. Furthermore, the consideration received by Sigma for the Pharmaceutical Business will allow it to establish a firm capital base from which to ensure an efficient business model. In recognition of this, the Pharmaceutical Business will commit to a long term supply, distribution and logistics arrangement with Sigma. 4. DETAILS OF THE SUBSEQUENT OFFER 4.1 Terms of the Subsequent Offer In terms of the Subsequent Offer, Aspen Global, or an entity nominated by Aspen Global, will acquire the Pharmaceutical Business, by acquiring either the business conducted by the Pharmaceutical Business or the shares in the subsidiaries of Sigma that carry on the Pharmaceutical Business and/or hold assets of the Pharmaceutical Business, or a combination of the aforementioned, for a cash consideration of A$900 million (approximately ZAR5 871 million1) on a debt-free basis. In terms of the Subsequent Offer, Sigma, which has agreed to deal exclusively with Aspen until 15 October 2010, will also accept a non-compete clause with the Pharmaceutical Business for a period of two years. 4.2 Funding The Subsequent Offer will be funded out of Aspen’s available cash resources as well as cash to be raised from its bankers. 4.3 Effective date The effective date of the implementation of the Subsequent Offer will be upon completion of the conditions precedent. 4.4 Conditions precedent The completion of the Subsequent Offer is subject to the satisfactory conclusion of limited conditions precedent which are normal for a transaction of this nature, including: conclusion of a Business and/or Share Purchase Agreement between Aspen and Sigma; all requisite regulatory approvals; and the approval of Sigma shareholders. 5. PRO FORMA FINANCIAL EFFECTS The unaudited pro-forma financial effects set out in the table below have been prepared to assist Aspen shareholders to assess the impact of the Subsequent Offer on the earnings per share (“EPS”) and headline EPS (“HEPS”) for the 6 months ended 31 December 2009, and the net asset value (“NAV”) per Aspen ordinary share as at 31 December 2009. The pro-forma financial effects have been prepared for illustrative purposes only and because of their nature, may not fairly present the effects of the Subsequent Offer on Aspen’s results of operations for the 6 months ended and the financial position at 31 December 2009. The Pharmaceutical Business results used are for the 6 months ended 31 January 2010. The Directors of Aspen are responsible for the preparation of the financial effects, which have not been reviewed by the auditors. Pre-adjustment For the six months ended 31 December 2009 Post-adjustment For the six months ended 31 December 2009 Actual “Before” (cents) (1,3,8) Pro-forma “After” the Subsequent Offer (1,2,4,6,7) (cents) % Change2 Actual “Before” (cents) (1,3,8) Pro-forma “After” the Subsequent Offer (1,2,5,6,7) (cents) % Change2 EPS 240.58 (134.36) (155.8) 240.58 252.54 5.0 HEPS 242.32 (132.61) (154.7) 242.32 254.28 4.9 NAV 2,192.98 2,192.98 0.0 2,192.98 2,192.98 0.0 Notes: 1. Extracted from

Aspen Pharmacare Holdings Limited (Incorporated in the Republic of South Africa) (Registration number 1985/002935/06) Share code: APN ISIN: ZAE000066692 (“Aspen”) Renewal of detailed cautionary announcement Aspen shareholders are referred to the detailed cautionary announcement dated 21 May 2010 and are advised that Aspen Global Incorporated (“Aspen Global”) has submitted to Sigma Pharmaceuticals Limited (“Sigma”), a confirmed offer to acquire the whole of Sigma (the “Transaction”) for cash at a price per Sigma share of A$0.55 (approx. ZAR3.58)1 (the “Offer”) which implies an equity value of A$648 million (approx. ZAR4 219 million)1 based on 1,178.6 million Sigma shares outstanding. Aspen has proposed that the Transaction be executed via a scheme of arrangement. The Offer is also subject to numerous conditions precedent, including the satisfactory completion by Aspen of a final due diligence investigation, the conclusion of a scheme implementation agreement and fulfillment of all necessary regulatory approvals. Aspen shareholders are referred to the announcement released today by Sigma, which is available at the ASX website www.asx.com.au. Accordingly, Aspen shareholders are advised to continue to exercise caution when dealing in Aspen shares until a further announcement is made. 1 Based on AUD/ZAR exchange rate of 0.1536 as at 7 July 2010 (Source: Bloomberg). Woodmead 7 July 2010